Pipeline of 19 rare disease lentiviral therapies buoyed by bluebird vote

Sweeping advisory committee support last week for two bluebird gene therapies bodes well for the at least nine other companies with lentivirus-based gene therapies in the clinic for rare diseases. 

According to BioCentury’s BCIQ database, at least 19 gene therapies that use lentiviral vectors to modify cells outside the body before returning them to the patient are in clinical testing...